Canaccord lowered the firm’s price target on Ocuphire Pharma (OCUP) to $10 from $18 and keeps a Buy rating on the shares. The firm noted they announced they will acquire Opus Genetics in all-stock transaction, gaining seven gene therapy programs for inherited retinal disease and will trade under a new symbol “IRD” on October 24th.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP: